Condition: Cancer · Ototoxicity, Drug-Induced · Quality of Life · Sponsor: Institut de Cancérologie de Lorraine
There are many undesirable effects associated with platinum-based cancer treatments (renal failure, anaemia, etc.). Their administration also leads to neurosensory problems such as ototoxicity, tinnitus and reduced hearing acuity. According to a the French survey (2018), 39.7% of people suffer from hearing problems due to cancer treatments, five years after a cancer diagnosis. Improving side effects such as hypoacusis and tinnitus can significantly improve patients' quality of life and adherence to treatment. Many clinical trials proposed a medicinal solution to patients receiving platinum-based cancer treatments but none has led to a consensus on management. The aim of the study is to offer patients receiving platinum-based chemotherapy and suffering from hearing problems a hearing aid to improve their quality of life.
This description comes directly from the study's public registry record.
JEAN LOUIS MERLIN, PUPH · +33 3 83 65 60 62 · jl.merlin@nancy.unicancer.fr
CECILE HUIN SCHOHN, PhD · +33 3 83 59 86 07 · c.huinschohn@nancy.unicancer.fr
Always discuss trial participation with your own doctor first.
| Institut de Cancerologie de Lorraine | Vandœuvre-lès-Nancy, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05936034